Global Assisted Reproductive Technology research

Assisted Reproductive Technology Comprehensive Study by Type (General, Fertility Medication, In Vitro Fertilization, Others), Application (Fertility Clinics, Hospitals, Others) Players and Region - Global Market Outlook to 2028

Assisted Reproductive Technology Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Assisted Reproductive Technology Market?

Assisted reproductive technology is included fertility treatments that handle both a woman's egg and a man's sperm. This technique involves surgically removing eggs from a woman’s ovaries, combining them with sperm in the laboratory, and returning them to the woman’s body or donating them to another woman. The most common and effective type of the assisted reproductive technology is in vitro fertilization (IVF). The factors such as Increased Prevalence of Infertility due to High Stress, Obesity, and Other Reasons and Increased Number of People with Sedatory Lifestyle are driving the global Assisted Reproductive Technology market. Also, the Growing Demand for In Vitro Fertilization (IVF) Technique fueling the market growth. However, Multiple Pregnancy due to Assisted Reproductive Technology is a Common Complication that may restrain the growth of the global Assisted Reproductive Technology market.

Highlights from Assisted Reproductive Technology Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledThermo Fisher Scientific (United States), Vitrolife (Sweden), Cosmos Biomedical Ltd. (United Kingdom), Ferring Pharmaceuticals (Switzerland), Nidacon International AB (Sweden), Irvine Scientific (United States), Merck Group (Germany), Cook Medical (United States), INVO Bioscience (United States) and Smiths Medical (United States)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Assisted Reproductive Technology market throughout the forecasted period.

Thermo Fisher Scientific (United States), Vitrolife (Sweden), Cosmos Biomedical Ltd. (United Kingdom), Ferring Pharmaceuticals (Switzerland), Nidacon International AB (Sweden), Irvine Scientific (United States), Merck Group (Germany), Cook Medical (United States), INVO Bioscience (United States) and Smiths Medical (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are EMD Serono Inc. (United States) and IVFtech (Denmark).

Assisted Reproductive Technology Market Segmentation:
ScopeSub-Segments
Application / End UserFertility Clinics, Hospitals and Others
TypeGeneral, Fertility Medication, In Vitro Fertilization and Others


On the basis of geography, the market of Assisted Reproductive Technology has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing Demand for In Vitro Fertilization (IVF) Technique

Market Growth Drivers:
Increased Prevalence of Infertility due to High Stress, Obesity, and Other Reasons and Increased Number of People with Sedatory Lifestyle

Challenges:
Less Awareness about Benefits of Assisted Reproductive Technology among People in Some Regions

Restraints:
Multiple Pregnancy due to Assisted Reproductive Technology is a Common Complication

Opportunities:
Growing Number of Fertility Centres across the Globe and Increasing Research and Development Investments

Key Target Audience
Assisted Reproductive Technology Providers, Emerging Companies, Research Professionals and End-users

Market Leaders & Development Strategies
In March 2020, Thermo Fisher Scientific Inc., the world leader in serving science, and QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies, has announced that their boards of directors, as well as the managing board of QIAGEN N.V., have unanimously approved Thermo Fisher's proposal to acquire QIAGEN.
In June 2019, Thermo Fisher Scientific entered into a global research collaboration with Predictive Laboratories, a wholly-owned subsidiary of Predictive Technology Group, Inc. (OTC PINK: PRED), focused on the study of genetic factors in female infertility. This work utilizes a range of products from Thermo Fisher for reproductive health, including Applied Biosystems CarrierScan Assay for whole exome sequencing, Ion ReproSeq PGS Assay, CytoScan Dx Assay, and Ion AmpliSeq Exome RDY.


Report Objectives / Segmentation Covered

By Type
  • General
  • Fertility Medication
  • In Vitro Fertilization
  • Others
By Application
  • Fertility Clinics
  • Hospitals
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Infertility due to High Stress, Obesity, and Other Reasons
      • 3.2.2. Increased Number of People with Sedatory Lifestyle
    • 3.3. Market Challenges
      • 3.3.1. Less Awareness about Benefits of Assisted Reproductive Technology among People in Some Regions
    • 3.4. Market Trends
      • 3.4.1. Growing Demand for In Vitro Fertilization (IVF) Technique
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Assisted Reproductive Technology, by Type, Application and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Assisted Reproductive Technology (Value)
      • 5.2.1. Global Assisted Reproductive Technology by: Type (Value)
        • 5.2.1.1. General
        • 5.2.1.2. Fertility Medication
        • 5.2.1.3. In Vitro Fertilization
        • 5.2.1.4. Others
      • 5.2.2. Global Assisted Reproductive Technology by: Application (Value)
        • 5.2.2.1. Fertility Clinics
        • 5.2.2.2. Hospitals
        • 5.2.2.3. Others
      • 5.2.3. Global Assisted Reproductive Technology Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Assisted Reproductive Technology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Thermo Fisher Scientific (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Vitrolife (Sweden)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Cosmos Biomedical Ltd. (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ferring Pharmaceuticals (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nidacon International AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Irvine Scientific (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Merck Group (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cook Medical (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. INVO Bioscience (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Smiths Medical (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Assisted Reproductive Technology Sale, by Type, Application and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Assisted Reproductive Technology (Value)
      • 7.2.1. Global Assisted Reproductive Technology by: Type (Value)
        • 7.2.1.1. General
        • 7.2.1.2. Fertility Medication
        • 7.2.1.3. In Vitro Fertilization
        • 7.2.1.4. Others
      • 7.2.2. Global Assisted Reproductive Technology by: Application (Value)
        • 7.2.2.1. Fertility Clinics
        • 7.2.2.2. Hospitals
        • 7.2.2.3. Others
      • 7.2.3. Global Assisted Reproductive Technology Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Assisted Reproductive Technology: by Type(USD Million)
  • Table 2. Assisted Reproductive Technology General , by Region USD Million (2017-2022)
  • Table 3. Assisted Reproductive Technology Fertility Medication , by Region USD Million (2017-2022)
  • Table 4. Assisted Reproductive Technology In Vitro Fertilization , by Region USD Million (2017-2022)
  • Table 5. Assisted Reproductive Technology Others , by Region USD Million (2017-2022)
  • Table 6. Assisted Reproductive Technology: by Application(USD Million)
  • Table 7. Assisted Reproductive Technology Fertility Clinics , by Region USD Million (2017-2022)
  • Table 8. Assisted Reproductive Technology Hospitals , by Region USD Million (2017-2022)
  • Table 9. Assisted Reproductive Technology Others , by Region USD Million (2017-2022)
  • Table 10. South America Assisted Reproductive Technology, by Country USD Million (2017-2022)
  • Table 11. South America Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 12. South America Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 13. Brazil Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 14. Brazil Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 15. Argentina Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 16. Argentina Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 17. Rest of South America Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 18. Rest of South America Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 19. Asia Pacific Assisted Reproductive Technology, by Country USD Million (2017-2022)
  • Table 20. Asia Pacific Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 21. Asia Pacific Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 22. China Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 23. China Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 24. Japan Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 25. Japan Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 26. India Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 27. India Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 28. South Korea Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 29. South Korea Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 30. Taiwan Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 31. Taiwan Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 32. Australia Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 33. Australia Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 34. Rest of Asia-Pacific Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 35. Rest of Asia-Pacific Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 36. Europe Assisted Reproductive Technology, by Country USD Million (2017-2022)
  • Table 37. Europe Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 38. Europe Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 39. Germany Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 40. Germany Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 41. France Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 42. France Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 43. Italy Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 44. Italy Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 45. United Kingdom Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 46. United Kingdom Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 47. Netherlands Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 48. Netherlands Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 49. Rest of Europe Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 50. Rest of Europe Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 51. MEA Assisted Reproductive Technology, by Country USD Million (2017-2022)
  • Table 52. MEA Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 53. MEA Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 54. Middle East Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 55. Middle East Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 56. Africa Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 57. Africa Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 58. North America Assisted Reproductive Technology, by Country USD Million (2017-2022)
  • Table 59. North America Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 60. North America Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 61. United States Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 62. United States Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 63. Canada Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 64. Canada Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 65. Mexico Assisted Reproductive Technology, by Type USD Million (2017-2022)
  • Table 66. Mexico Assisted Reproductive Technology, by Application USD Million (2017-2022)
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Assisted Reproductive Technology: by Type(USD Million)
  • Table 78. Assisted Reproductive Technology General , by Region USD Million (2023-2028)
  • Table 79. Assisted Reproductive Technology Fertility Medication , by Region USD Million (2023-2028)
  • Table 80. Assisted Reproductive Technology In Vitro Fertilization , by Region USD Million (2023-2028)
  • Table 81. Assisted Reproductive Technology Others , by Region USD Million (2023-2028)
  • Table 82. Assisted Reproductive Technology: by Application(USD Million)
  • Table 83. Assisted Reproductive Technology Fertility Clinics , by Region USD Million (2023-2028)
  • Table 84. Assisted Reproductive Technology Hospitals , by Region USD Million (2023-2028)
  • Table 85. Assisted Reproductive Technology Others , by Region USD Million (2023-2028)
  • Table 86. South America Assisted Reproductive Technology, by Country USD Million (2023-2028)
  • Table 87. South America Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 88. South America Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 89. Brazil Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 90. Brazil Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 91. Argentina Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 92. Argentina Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 93. Rest of South America Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 94. Rest of South America Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 95. Asia Pacific Assisted Reproductive Technology, by Country USD Million (2023-2028)
  • Table 96. Asia Pacific Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 97. Asia Pacific Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 98. China Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 99. China Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 100. Japan Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 101. Japan Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 102. India Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 103. India Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 104. South Korea Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 105. South Korea Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 106. Taiwan Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 107. Taiwan Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 108. Australia Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 109. Australia Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 110. Rest of Asia-Pacific Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 111. Rest of Asia-Pacific Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 112. Europe Assisted Reproductive Technology, by Country USD Million (2023-2028)
  • Table 113. Europe Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 114. Europe Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 115. Germany Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 116. Germany Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 117. France Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 118. France Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 119. Italy Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 120. Italy Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 121. United Kingdom Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 122. United Kingdom Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 123. Netherlands Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 124. Netherlands Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 125. Rest of Europe Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 126. Rest of Europe Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 127. MEA Assisted Reproductive Technology, by Country USD Million (2023-2028)
  • Table 128. MEA Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 129. MEA Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 130. Middle East Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 131. Middle East Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 132. Africa Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 133. Africa Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 134. North America Assisted Reproductive Technology, by Country USD Million (2023-2028)
  • Table 135. North America Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 136. North America Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 137. United States Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 138. United States Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 139. Canada Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 140. Canada Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 141. Mexico Assisted Reproductive Technology, by Type USD Million (2023-2028)
  • Table 142. Mexico Assisted Reproductive Technology, by Application USD Million (2023-2028)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Assisted Reproductive Technology: by Type USD Million (2017-2022)
  • Figure 5. Global Assisted Reproductive Technology: by Application USD Million (2017-2022)
  • Figure 6. South America Assisted Reproductive Technology Share (%), by Country
  • Figure 7. Asia Pacific Assisted Reproductive Technology Share (%), by Country
  • Figure 8. Europe Assisted Reproductive Technology Share (%), by Country
  • Figure 9. MEA Assisted Reproductive Technology Share (%), by Country
  • Figure 10. North America Assisted Reproductive Technology Share (%), by Country
  • Figure 11. Global Assisted Reproductive Technology share by Players 2022 (%)
  • Figure 12. Global Assisted Reproductive Technology share by Players (Top 3) 2022(%)
  • Figure 13. Global Assisted Reproductive Technology share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 16. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 17. Vitrolife (Sweden) Revenue, Net Income and Gross profit
  • Figure 18. Vitrolife (Sweden) Revenue: by Geography 2022
  • Figure 19. Cosmos Biomedical Ltd. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. Cosmos Biomedical Ltd. (United Kingdom) Revenue: by Geography 2022
  • Figure 21. Ferring Pharmaceuticals (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Ferring Pharmaceuticals (Switzerland) Revenue: by Geography 2022
  • Figure 23. Nidacon International AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 24. Nidacon International AB (Sweden) Revenue: by Geography 2022
  • Figure 25. Irvine Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 26. Irvine Scientific (United States) Revenue: by Geography 2022
  • Figure 27. Merck Group (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Merck Group (Germany) Revenue: by Geography 2022
  • Figure 29. Cook Medical (United States) Revenue, Net Income and Gross profit
  • Figure 30. Cook Medical (United States) Revenue: by Geography 2022
  • Figure 31. INVO Bioscience (United States) Revenue, Net Income and Gross profit
  • Figure 32. INVO Bioscience (United States) Revenue: by Geography 2022
  • Figure 33. Smiths Medical (United States) Revenue, Net Income and Gross profit
  • Figure 34. Smiths Medical (United States) Revenue: by Geography 2022
  • Figure 35. Global Assisted Reproductive Technology: by Type USD Million (2023-2028)
  • Figure 36. Global Assisted Reproductive Technology: by Application USD Million (2023-2028)
  • Figure 37. South America Assisted Reproductive Technology Share (%), by Country
  • Figure 38. Asia Pacific Assisted Reproductive Technology Share (%), by Country
  • Figure 39. Europe Assisted Reproductive Technology Share (%), by Country
  • Figure 40. MEA Assisted Reproductive Technology Share (%), by Country
  • Figure 41. North America Assisted Reproductive Technology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Thermo Fisher Scientific (United States)
  • Vitrolife (Sweden)
  • Cosmos Biomedical Ltd. (United Kingdom)
  • Ferring Pharmaceuticals (Switzerland)
  • Nidacon International AB (Sweden)
  • Irvine Scientific (United States)
  • Merck Group (Germany)
  • Cook Medical (United States)
  • INVO Bioscience (United States)
  • Smiths Medical (United States)
Additional players considered in the study are as follows:
EMD Serono Inc. (United States) , IVFtech (Denmark)
Select User Access Type

Key Highlights of Report


Apr 2023 230 Pages 89 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Assisted Reproductive Technology research Quantitative research analysis
Global Assisted Reproductive Technology research Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"Increased Prevalence of Infertility due to High Stress, Obesity, and Other Reasons " is seen as one of major growth factors of Assisted Reproductive Technology Market in years to come.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
The Assisted Reproductive Technology market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Assisted Reproductive Technology research Report?

Have a Query? Click Here

Other Related Reports

Health Oxygen Plant Comprehensive Study by Type (Cryogenic Oxygen/Nitrogen Plants, PSA Based Oxygen Plants, VPSA Oxygen Plants), Application (Metal industry, Chemical and petrochemical industries, Oi...
$ 3750
Healthcare Revenue Cycle Management Comprehensive Study by Type (Integrated, Standalone), Application (Hospitals, Physicians, Diagnostic & Ambulatory Care Centers), Function (Claims & Denial Manageme...
$ 3750
Electronic Medical Record Comprehensive Study by Type (Inpatient Electronic Medical Record, Ambulatory Electronic Medical Record), Application (Clinical, Administrative, Reporting in Healthcare Syste...
$ 3750
Virtual Reality In Healthcare Comprehensive Study by Type (VR Semiconductor Components, VR Devices, VR Sensors, Others), Application (Rehabilitation and therapy procedures, Surgery, Visualization, Ed...
$ 3750
Healthcare IT Outsourcing Comprehensive Study by Type (Electronic Health Record (EHR), Payer HCIT Outsourcing, Operational HCIT Outsourcing, Life Sciences HCIT Outsourcing, I.T Infrastructure Outsour...
$ 3650
Healthcare IOT Security Comprehensive Study by Type (Hardware, Software, Services), Application (Patient monitoring and communication, Patient drug supply, Electronic health implants, Hospital and bu...
$ 3750